Peptides modulating conformational changes in secreted chaperones: From in silico design to preclinical proof of concept

Blocking conformational changes in biologically active proteins holds therapeutic promise. Inspired by the susceptibility of viral entry to inhibition by synthetic peptides that block the formation of helix–helix interactions in viral envelope proteins, we developed a computational approach for predicting interacting helices. Using this approach, which combines correlated mutations analysis and Fourier transform, we designed peptides that target gp96 and clusterin, 2 secreted chaperones known to shift between inactive and active conformations. In human blood mononuclear cells, the gp96-derived peptide inhibited the production of TNFα, IL-1β, IL-6, and IL-8 induced by endotoxin by >80%. When injected into mice, the peptide reduced circulating levels of endotoxin-induced TNFα, IL-6, and IFNγ by >50%. The clusterin-derived peptide arrested proliferation of several neoplastic cell lines, and significantly enhanced the cytostatic activity of taxol in vitro and in a xenograft model of lung cancer. Also, the predicted mode of action of the active peptides was experimentally verified. Both peptides bound to their parent proteins, and their biological activity was abolished in the presence of the peptides corresponding to the counterpart helices. These data demonstrate a previously uncharacterized method for rational design of protein antagonists.

[1]  M. Fenton,et al.  Differential Involvement of BB Loops of Toll-IL-1 Resistance (TIR) Domain-Containing Adapter Proteins in TLR4- versus TLR2-Mediated Signal Transduction 1 , 2005, The Journal of Immunology.

[2]  Hongzhe Li,et al.  Statistical methods for analysis of time course gene expression data. , 2002, Frontiers in bioscience : a journal and virtual library.

[3]  D. Eisenberg,et al.  The hydrophobic moment detects periodicity in protein hydrophobicity. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Gleave,et al.  Antisense clusterin oligodeoxynucleotides increase the response of HER‐2 gene amplified breast cancer cells to Trastuzumab , 2005, Journal of cellular physiology.

[5]  P. Srivastava,et al.  A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients , 2006, Cancer Immunology, Immunotherapy.

[6]  M. Gleave,et al.  Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. , 2004, The Journal of urology.

[7]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[8]  G. Hart,et al.  Glycobiology and Cancer: Meeting Summary and Future Directions , 2004, Cancer biology & therapy.

[9]  M. Gleave,et al.  Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. , 2005, Neoplasia.

[10]  J. Wilce,et al.  pH-dependent changes in the in vitro ligand-binding properties and structure of human clusterin. , 2000, Biochemistry.

[11]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Zihai Li,et al.  Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Boris Hadaschik,et al.  The role of stress proteins in prostate cancer. , 2007, Current genomics.

[14]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[15]  P. Srivastava,et al.  Specific Immunogenicity of Heat Shock Protein gp96 Derives from Chaperoned Antigenic Peptides and Not from Contaminating Proteins1 , 2007, The Journal of Immunology.

[16]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[17]  Shibo Jiang,et al.  HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains , 2007, Journal of Biological Chemistry.

[18]  A. Bolhassani,et al.  Heat-shock proteins as powerful weapons in vaccine development , 2008, Expert review of vaccines.

[19]  R. Blumenthal,et al.  Conformational Changes in Cell Surface HIV-1 Envelope Glycoproteins Are Triggered by Cooperation between Cell Surface CD4 and Co-receptors* , 1998, The Journal of Biological Chemistry.

[20]  S. Yeh,et al.  Isolation of Ku70-binding proteins (KUBs). , 1999, Nucleic acids research.

[21]  Amy S. Lee,et al.  ER chaperones in mammalian development and human diseases , 2007, FEBS letters.

[22]  M. Gleave,et al.  Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer , 2005, World Journal of Urology.

[23]  Haihong Fan,et al.  Conformational lability of two molecular chaperones Hsc70 and gp96: effects of pH and temperature. , 2006, Archives of biochemistry and biophysics.

[24]  Haim Ashkenazy,et al.  Optimal data collection for correlated mutation analysis , 2009, Proteins.

[25]  Jaime Prilusky,et al.  Automated analysis of interatomic contacts in proteins , 1999, Bioinform..

[26]  Zihai Li,et al.  An integrated view of the roles and mechanisms of heat shock protein gp96-peptide complex in eliciting immune response. , 2002, Frontiers in bioscience : a journal and virtual library.

[27]  M. Gleave,et al.  Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. , 2005, Oncology reports.

[28]  S. Calderwood,et al.  Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation , 2008, Expert review of vaccines.

[29]  D. Burton,et al.  Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor , 2008, Nature.

[30]  M. Gleave,et al.  A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer , 2008, Clinical Cancer Research.

[31]  S. Sastry,et al.  Molecular Mechanisms of Peptide Loading by the Tumor Rejection Antigen/Heat Shock Chaperone gp96 (GRP94)* , 1999, The Journal of Biological Chemistry.

[32]  M. Gleave,et al.  Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo , 2005, Molecular Cancer Therapeutics.

[33]  C. Sander,et al.  Correlated mutations and residue contacts in proteins , 1994, Proteins.

[34]  S. Durell,et al.  Dilation of the influenza hemagglutinin fusion pore revealed by the kinetics of individual cell-cell fusion events , 1996, The Journal of cell biology.

[35]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[36]  M. Gleave,et al.  Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. , 2004, Molecular cancer therapeutics.

[37]  S. A. Gallo,et al.  Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion , 2006, Retrovirology.

[38]  T. Ørntoft,et al.  Clusterin Expression in Normal Mucosa and Colorectal Cancer*S , 2007, Molecular & Cellular Proteomics.

[39]  C. Garrido,et al.  Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy , 2007, Journal of leukocyte biology.

[40]  C. Brown,et al.  Clusterin, a binding protein with a molten globule-like region. , 2001, Biochemistry.

[41]  Pierre Baldi,et al.  Accurate Prediction of Protein Disordered Regions by Mining Protein Structure Data , 2005, Data Mining and Knowledge Discovery.

[42]  P. Srivastava,et al.  Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. , 2007, Immunity.

[43]  Joseph Rosenbluh,et al.  Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium , 2007, Proceedings of the National Academy of Sciences.

[44]  R. Medzhitov,et al.  TLR4 Up-Regulation at Protein or Gene Level Is Pathogenic for Lupus-Like Autoimmune Disease1 , 2006, The Journal of Immunology.

[45]  C. Sander,et al.  Correlated Mutations and Residue Contacts , 1994 .

[46]  S. Vogel,et al.  Cell-penetrating TIR BB loop decoy peptides , 2007, Expert opinion on biological therapy.

[47]  Alfonso Valencia,et al.  A graphical interface for correlated mutations and other protein structure prediction methods , 1997, Comput. Appl. Biosci..

[48]  A. Villa,et al.  Human Plasmacytoid Dendritic Cells Interact with gp96 via CD91 and Regulate Inflammatory Responses1 , 2008, The Journal of Immunology.

[49]  Y. Shai,et al.  A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus‐cell fusion: an emerging similarity with functional domains of other viruses. , 1995, The EMBO journal.

[50]  Kevin Karplus,et al.  Contact prediction using mutual information and neural nets , 2007, Proteins.

[51]  M. Gleave,et al.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. , 2005, Journal of the National Cancer Institute.

[52]  P. S. Kim,et al.  A spring-loaded mechanism for the conformational change of influenza hemagglutinin , 1993, Cell.

[53]  J. Lakins,et al.  Evidence that clusterin has discrete chaperone and ligand binding sites. , 2002, Biochemistry.

[54]  K. Guthrie,et al.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. , 1996, Biochemistry.

[55]  G. Sapiro,et al.  Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.

[56]  D. Lambert,et al.  Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Taichman,et al.  Clusterin inhibits apoptosis by interacting with activated Bax , 2005, Nature Cell Biology.

[58]  Pierre Baldi,et al.  Improved residue contact prediction using support vector machines and a large feature set , 2007, BMC Bioinformatics.

[59]  R. Binder,et al.  Essential role of CD91 in re-presentation of gp96-chaperoned peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Gregory A Caputo,et al.  Supporting Online Material for Computational Design of Peptides That Target Transmembrane Helices , 2007 .

[61]  M. Fenton,et al.  Cutting Edge: Differential Inhibition of TLR Signaling Pathways by Cell-Permeable Peptides Representing BB Loops of TLRs1 , 2007, The Journal of Immunology.

[62]  M. Gleave,et al.  Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. , 2005, Oncology reports.

[63]  P. Gray,et al.  Extracellular Heat Shock Proteins in Cell Signaling and Immunity , 2007, Annals of the New York Academy of Sciences.